DIWALI SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim Offer →
logo

BETA vs KPL: Stock Comparison

BETA DRUGS vs KWALITY PHARMACEUTICALS LUpdated 6 Nov 26, 4:08 PM ISTNSE & company filings

KWALITY PHARMACEUTICALS L is the larger company by market capitalisation. BETA DRUGS shows a lower P/E and a higher ROCE, while KWALITY PHARMACEUTICALS L shows a higher ROE, lower leverage and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

BETA leads 5; KPL leads 5 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

BETAKPL

Valuation lens

What price are you paying?

Market CapContext only
₹2,011 Cr
₹3,762 Cr
P/E RatioBETA has the lower reading
35.56x ✓
46.42x
P/B RatioBETA has the lower reading
4.19x ✓
11.35x
EPSKPL has the higher reading
₹18
₹24.7 ✓
Book ValueContext only
₹220.09
₹317.96
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
KPL is the larger company
₹3,762 Cr vs ₹2,011 Cr
P/E Ratio
BETA has a lower P/E
35.56x vs 46.42x
P/B Ratio
BETA has a lower P/B
4.19x vs 11.35x
EPS
KPL has higher earnings per share
₹24.7 vs ₹18
Qtr Sales Growth
BETA has stronger quarterly sales growth
9.51% vs 3.33%
Qtr Profit Growth
BETA has stronger quarterly profit growth
16.98% vs 1.23%
ROE
KPL has a higher ROE
20.41% vs 14.79%
ROCE
BETA has a higher ROCE
18.03% vs 17.47%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Price

MetricBETAKPL
Live Price₹1,805.9₹3,644.8
Day Change-1.89%-1.15%
Volume15,89920,631
52-Week High₹2,807.9₹3,949
52-Week Low₹990.1₹1,561
Distance from 52W High-35.69%-7.7%

Valuation

MetricBETAKPL
Market Cap₹2,011 Cr₹3,762 Cr
P/E Ratio35.56x46.42x
P/B Ratio4.19x11.35x
EPS₹18₹24.7
Book Value₹220.09₹317.96
Dividend Yield0%0%

Growth

MetricBETAKPL
Revenue Growth (TTM YoY)0%0%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth9.51%3.33%
Qtr Profit Growth16.98%1.23%

Profitability & Leverage

MetricBETAKPL
ROE14.79%20.41%
ROCE18.03%17.47%
Net Margin10.78%13.39%
Operating Margin16.79%19.97%
Debt to Equity0.6x0.4x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricBETAKPL
Promoter Holding58.91%▼ 0.19 pp54.86%▼ 0.01 pp
FII Holding1.37%▲ 0.35 pp3.13%▲ 0.34 pp
DII Holding6.45%▲ 0.22 pp0.56%▲ 0.2 pp
Public Holding33.27%▼ 0.38 pp41.44%▼ 0.54 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BETA DRUGS and KWALITY PHARMACEUTICALS L.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.